Oncolytic Virus Therapy Market Size, Insights, Outlook, and Overview by 2024-2033

Overview and Scope

Oncolytic virus therapy, also known as virotherapy, is a type of cancer treatment that utilizes viruses to target and destroy cancer cells in the body. The main objective of oncolytic virus therapy is to use viruses that have been genetically modified or naturally occur in a way that allows them to selectively infect and replicate within cancer cells while sparing healthy cells.

Sizing and Forecast

The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.15 billion in 2023 to $0.19 billion in 2024 at a compound annual growth rate (CAGR) of 26.2%. The growth in the historic period can be attributed to improved genetic engineering technique, increased understanding of tumor microenvironment, clinical successes and regulatory approvals, rise of immunotherapy in cancer treatment, advancements in gene delivery systems.

The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.44 billion in 2028 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to expansion of oncolytic virus platforms, combination therapies with immune checkpoint inhibitors, personalized medicine approaches, expansion of clinical trial landscape, regulatory support and guidelines. Major trends in the forecast period include technological advances in delivery systems, advancements in synthetic biology, collaborations and partnerships in biopharmaceutical industry, advancements in virology and immunology, focus on pediatric oncology.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Segmentation & Regional Insights

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

North America was the largest region in the oncolytic virus therapy market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of cancer cases is expected to propel the growth of the oncolytic virus therapy market going forward. Cancer is a term used to describe a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Oncolytic virus therapy offers the potential to selectively target and destroy cancer cells while stimulating an immune response against the tumor, providing a dual mechanism of action for effective cancer treatment. For instance, in January 2023, according to the American Cancer Society Inc., a US-based non-profit organization, it is anticipated that there will be 609,820 cancer deaths and 1,958,310 new cancer cases in the US during 2022. Therefore, the increasing prevalence of cancer cases is driving the growth of the oncolytic virus therapy market.

Key Industry Players

Major companies operating in the oncolytic virus therapy market report are Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Eurofins Scientific SE, Recipharm AB, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics, SillaJen Inc.

The oncolytic virus therapy market report table of contents includes:

1. Executive Summary

2. Oncolytic Virus Therapy Market Characteristics

3. Oncolytic Virus Therapy Market Trends And Strategies

4. Oncolytic Virus Therapy Market – Macro Economic Scenario

5. Global Oncolytic Virus Therapy Market Size and Growth

…

32. Global Oncolytic Virus Therapy Market Competitive Benchmarking

33. Global Oncolytic Virus Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oncolytic Virus Therapy Market

35. Oncolytic Virus Therapy Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model